|Bid||173.50 x 1100|
|Ask||173.64 x 1300|
|Day's Range||167.63 - 174.10|
|52 Week Range||139.80 - 194.92|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||69.07|
|Earnings Date||Jan 29, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||201.36|
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) due to its excellent fundamentals in more Read More...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Might be worth writing up a second gift wishlist, and this time devote it solely to stocks. TheStreet contributor Tip Ranks has five "strong buy" stocks for investors looking to add to their portfolio. "We used TipRanks market data to pinpoint stocks with a 'Strong Buy' consensus from the Street's best-performing analysts.
Plus we can turn to the average analyst price target to get a handle on the kind of upside investors can look forward to. This comes with a $56 average analyst price target (15% upside potential). MKM Partners Roxanne Meyer has just returned from a store visit alongside TJX management.
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.
Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / U.S. markets closed up on Tuesday as gains in defensive stocks helped counteract trade related concerns between U.S. and China. The Dow Jones Industrial ...
Investing.com - The Dow closed higher Tuesday as investor concerns over trade appeared to ease after U.S. economic advisor Larry Kudlow offered some hope of a deal with China.
Investing.com – Vertex Pharmaceuticals, Delta Air Lines and L Brands jumped Tuesday, helping the broader market rebound from session lows.
Vertex Pharmaceuticals jumped Tuesday after a key study showed its triple pill could work as a cystic fibrosis treatment for two patient groups.
Stocks turned higher in afternoon trade Tuesday. In stock news today, Delta Air Lines led an airline rally, while Verizon was a top gainer in the Dow.
Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent. The company said the combination regimen, comprising its experimental agent VX-659 and its other CF drugs Kalydeco and tezacaftor, showed a 10 percentage point improvement in lung function in patients compared to those treated with placebo and the other two drugs. Wall Street analysts lauded the results, and said the drug regimen could improve the standard of life for some cystic fibrosis patients.
The company is currently testing a different regimen of three drugs — including two of its existing products — that it hopes will treat 90 percent of cystic fibrosis patients.
-Mean absolute improvement in ppFEV1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p&